On June 25th, GeLongHui reported that Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd. (referred to as 'Node Pharmaceutical'), recently received the 'Drug Registration Certificate' issued and approved by the National Medical Products Administration regarding the Empagliflozin tablets.
Empagliflozin tablets are a kind of Sodium-glucose cotransporter 2 (SGLT-2) inhibitor, used to treat type 2 diabetes and heart failure in adult patients. Node Pharmaceutical's Empagliflozin tablets (10mg, 25mg) were accepted by the National Medical Products Administration in February 2023, and as of the end of May 2024, the company and its subsidiaries had accumulated R&D investment of approximately 8.3714 million yuan for this product.